Fig. 9

Guadecitabine/ICBs reduce the percentages of immune suppressive T cells more efficiently than guadecitabine alone, increase IFN-γ production and reduce angiogenesis. A mIF analysis of lung tumor tissue slides (n=3-6 mice/group) showing cell densities of CD4+Foxp3+ regulatory cells, percentages of CD4+FoxP3+ among total CD4+ T cells and percent of CD4+Foxp3+ cells in 30µm proximity to CD8+ cells in tumor nodules from mice receiving different treatments. B percentages of CD8+CD28-CD39+ cells in the lung from mice receiving different treatments. C mIF analysis of lung tumor tissue slides (n=3-6 mice/group) showing CD8+, and CD4+FoxP3- cell densities from mice receiving different treatments. D serum levels expressed in pg/ml of Th1 cytokines in response to different in vivo treatments by Milliplex assay (n=7 mice/group). E serum levels expressed in pg/ml of IL-17 cytokine in response to different in vivo treatments by Milliplex assay (n=7 mice/group). F serum levels expressed in pg/ml of Th2 cytokines in response to different in vivo treatments by Milliplex assay (n=7 mice/group). G serum levels expressed in pg/ml of chemokines involved in angiogenesis regulation in response to different in vivo treatments by Milliplex assay (n=7 mice/group). H mIF analysis of lung tumor tissue slides (n=3-6 mice/group) showing the percentage of area occupied by CD31+cells from mice receiving different treatments. *p<0.05, **p<0.02, ***p<0.01, ****p<0.001